Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Related Topics:
Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
WuXi AppTec was expected to release its half-year earnings results on August 3. Photo: Handout
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

videocam
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
26
Illustration: Victor Sanjinez
US-China relations

US National Science Foundation to ban projects with flagged Chinese institutions

Raising security fears, NSF moves from case-by-case approval to full ban on working with restricted entities and their employees.

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Advertisement
Advertisement
Advertisement
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

Royalty Pharma is scouting the Asia-Pacific region for innovative biotechnology start-ups with late-stage pharmaceutical pipelines. Photo: Shutterstock
China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock
China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

US-China trade war

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

videocam
13
Chinese biotech companies have risen up the value chain in recent years, with cross-border licensing deals worth a record US$60 billion in the first quarter of 2026, according to the National Medical Products Administration. Photo: Getty Images
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
US-China relations

Opinion | How US tech hegemony is locking out the Global South

The world deserves better than a monopoly that builds walls and hobbles development.

videocam
4
China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

Advertisement
Advertisement
Advertisement
China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Illustration by Henry Wong
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
China’s private sector

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

In China, investigator-initiated trials allow drug makers to generate human clinical data “faster” than the conventional regulatory process. Photo: Shutterstock
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

China trade

China supply chain expo set to welcome more US firms, launch AI section

Amid trade tensions, China Council for the Promotion of International Trade describes business communities as a ‘bridge’ for exchanges.

videocam
Robots at the Nvidia booth at the third China International Supply Chain Expo in Beijing in July 2025. Photo: Xinhua
Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

The recent wave of investment in AI drug development aligns with Beijing’s drive for technological self-sufficiency. Photo: Shutterstock
Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement